Loading...
XKRX033270
Market cap181mUSD
Jan 02, Last price  
18,140.00KRW
1D
-0.38%
1Q
-12.79%
Jan 2017
-1.95%
IPO
347.47%
Name

Korea United Pharm Inc

Chart & Performance

D1W1MN
XKRX:033270 chart
P/E
5.53
P/S
0.96
EPS
3,280.60
Div Yield, %
2.20%
Shrs. gr., 5y
-0.11%
Rev. gr., 5y
5.65%
Revenues
278.94b
+6.26%
67,591,173,00059,695,984,00094,700,346,000119,084,235,000134,958,313,000145,453,052,970134,829,851,010136,891,130,450155,189,552,760162,045,984,970176,905,089,970197,023,264,150211,935,529,520221,310,874,550215,949,552,650221,039,962,910262,522,022,550278,943,296,810
Net income
48.26b
+6.60%
3,950,757,0005,575,526,0008,874,396,00014,199,566,00016,843,455,00020,208,058,00016,378,830,02012,212,392,03018,374,835,73021,721,432,86019,513,764,60027,863,650,61031,672,447,39030,915,946,39026,613,256,99028,648,749,06045,275,093,91048,261,713,560
CFO
50.65b
-20.59%
9,748,487,0003,403,072,0007,052,230,00018,592,288,00016,513,470,00027,617,981,46022,221,118,10018,968,292,20021,314,121,92025,958,328,35030,021,142,51027,682,926,11036,862,476,78038,154,022,07036,962,044,55044,085,211,25063,782,033,40050,648,511,719
Dividend
Dec 27, 2023420 KRW/sh
Earnings
Mar 17, 2025

Profile

Korea United Pharm Inc. engages in the manufacture and sale of pharmaceutical products in South Korea. It offers products in the areas of respiratory system, musculo-skeletal system, gastro-intestinal tract system, cardiovascular system, anti-cancer, anti-infectives, allergy, immune system, central nervous system, and other diseases, as well OTC drugs. The company also exports its products to approximately 40 countries. Korea United Pharm Inc. was founded in 1987 and is headquartered in Seoul, South Korea.
URL
https://www.kup.co.kr
IPO date
Oct 23, 2007
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
278,943,297
6.26%
262,522,023
18.77%
Cost of revenue
189,918,152
167,457,925
Unusual Expense (Income)
NOPBT
89,025,145
95,064,097
NOPBT Margin
31.92%
36.21%
Operating Taxes
11,821,920
8,149,721
Tax Rate
13.28%
8.57%
NOPAT
77,203,224
86,914,376
Net income
48,261,714
6.60%
45,275,094
58.04%
Dividends
(5,883,219)
(5,492,002)
Dividend yield
1.48%
1.62%
Proceeds from repurchase of equity
(1,957,887)
(3,046,556)
BB yield
0.49%
0.90%
Debt
Debt current
28,506,553
22,067,139
Long-term debt
12,771,511
9,230,404
Deferred revenue
16,687
Other long-term liabilities
4,875,331
5,159,438
Net debt
(169,277,588)
(11,838,472)
Cash flow
Cash from operating activities
50,648,512
63,782,033
CAPEX
(31,309,034)
(24,207,240)
Cash from investing activities
(56,410,255)
(87,902,212)
Cash from financing activities
2,545,844
(10,585,756)
FCF
40,141,037
73,646,979
Balance
Cash
151,052,327
142,631,399
Long term investments
59,503,325
(99,495,384)
Excess cash
196,608,488
30,009,914
Stockholders' equity
383,585,318
349,619,837
Invested Capital
227,286,919
337,482,751
ROIC
27.34%
28.80%
ROCE
20.96%
25.82%
EV
Common stock shares outstanding
14,725
14,902
Price
27,000.00
18.68%
22,750.00
-51.95%
Market cap
397,581,480
17.27%
339,021,751
-52.07%
EV
228,303,892
327,183,280
EBITDA
99,119,320
104,052,652
EV/EBITDA
2.30
3.14
Interest
1,619,140
815,537
Interest/NOPBT
1.82%
0.86%